Super Vision Technology’s i-NYS Implantable Device Approved in China, Breaking the Treatment Barrier for Congenital Nystagmus

AI Briefing

• – Super Vision Technology's i-NYS implantable device approved in China for treating congenital nystagmus, marking a major breakthrough in ophthalmology.
• – The device, which stimulates the muscles that control eye movement, has been officially authorized for commercialization in China.
• – This approval paves the way for a new treatment option for patients with congenital nystagmus in the country.